Answers are grounded in this paper and cite their sources.
Systematic review demonstrates cost-effectiveness of SGLT2 inhibitors in heart failure patients, suggesting further comparisons are needed.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Rezaeian et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: